| Evolution of low HER2 expression between early and advanced-stage breast cancer P Tarantino, S Gandini, E Nicolò, P Trillo, F Giugliano, P Zagami, ... European Journal of Cancer 163, 35-43, 2022 | 123 | 2022 |
| Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives E Nicolò, F Giugliano, L Ascione, P Tarantino, C Corti, SM Tolaney, ... Cancer Treatment Reviews 106, 102395, 2022 | 78 | 2022 |
| Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion F Conforti, L Pala, E Pagan, V Bagnardi, T De Pas, P Queirolo, ... Clinical Cancer Research 27 (15), 4311-4324, 2021 | 60 | 2021 |
| Antibody–drug conjugates for the treatment of breast cancer C Corti, F Giugliano, E Nicolò, L Ascione, G Curigliano Cancers 13 (12), 2898, 2021 | 57 | 2021 |
| Management of cardiac toxicity induced by chemotherapy D Trapani, P Zagami, E Nicolò, G Pravettoni, G Curigliano Journal of Clinical Medicine 9 (9), 2885, 2020 | 42 | 2020 |
| Antibody–drug conjugates in breast cancer: the chemotherapy of the future? E Nicolo, P Zagami, G Curigliano Current opinion in oncology 32 (5), 494-502, 2020 | 34 | 2020 |
| The HER2-low revolution in breast oncology: steps forward and emerging challenges E Nicolò, L Boscolo Bielo, G Curigliano, P Tarantino Therapeutic Advances in Medical Oncology 15, 17588359231152842, 2023 | 23 | 2023 |
| HER2-low breast cancer: a new subtype? C Corti, F Giugliano, E Nicolo, P Tarantino, C Criscitiello, G Curigliano Current Treatment Options in Oncology 24 (5), 468-478, 2023 | 19 | 2023 |
| Novel immune targets for the treatment of triple-negative breast cancer C Corti, E Nicolò, G Curigliano Expert Opinion on Therapeutic Targets 25 (10), 815-834, 2021 | 19 | 2021 |
| Biosimilars for breast cancer B Migliavacca Zucchetti, E Nicolò, G Curigliano Expert opinion on biological therapy 19 (10), 1015-1021, 2019 | 14 | 2019 |
| Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe? C Corti, G Antonarelli, C Valenza, E Nicolò, H Rugo, J Cortés, N Harbeck, ... European Journal of Cancer 171, 25-42, 2022 | 12 | 2022 |
| Biology and treatment of HER2-low breast cancer E Nicolò, P Tarantino, G Curigliano Hematology/Oncology Clinics 37 (1), 117-132, 2023 | 8 | 2023 |
| Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases P Trillo, J Sandoval, D Trapani, E Nicolò, P Zagami, F Giugliano, ... European Journal of Cancer 185, 119-130, 2023 | 7 | 2023 |
| Antibody-drug conjugates in breast cancer: what is beyond HER2? E Nicolò, M Repetto, LB Bielo, P Tarantino, G Curigliano The Cancer Journal 28 (6), 436-445, 2022 | 7 | 2022 |
| Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations E Nicolò, D Trapani, PPMB Giachetti, P Zagami, G Curigliano Cancer treatment reviews 100, 102281, 2021 | 7 | 2021 |
| Metaplastic breast cancer: an all-round multidisciplinary consensus G Corso, C Criscitiello, L Nicosia, F Pesapane, E Vicini, F Magnoni, ... European Journal of Cancer Prevention 32 (4), 348-363, 2023 | 6 | 2023 |
| Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer. LS Munoz-Arcos, E Nicolò, MS Serafini, L Gerratana, C Reduzzi, ... International Review of Cell and Molecular Biology 381, 1-21, 2023 | 5 | 2023 |
| Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape J Uliano, E Nicolò, C Corvaja, B Taurelli Salimbeni, D Trapani, ... Expert Review of Clinical Pharmacology 15 (12), 1399-1413, 2022 | 4 | 2022 |
| PIK3CAMutations in breast cancer subtypes other than HR-positive/HER2-negative L Ascione, P Zagami, E Nicolò, E Crimini, G Curigliano, C Criscitiello Journal of Personalized Medicine 12 (11), 1793, 2022 | 4 | 2022 |
| Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population L Mazzarella, F Giugliano, E Nicolo, A Esposito, E Crimini, G Tini, J Uliano, ... The Oncologist 29 (2), e266-e274, 2024 | 3 | 2024 |
